Hemochromatosis E83.1

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 13.10.2022

Dieser Artikel auf Deutsch

Synonym(s)

Bronze Diabetes; Cirrhosis pigmentaire diabétique; Iron storage disease; Siderophilia; Siderosis; Troisier-Hanot-Chauffard Syndrome

History
This section has been translated automatically.

Troisier, 1871; Hanot and Chauffard, 1882

Definition
This section has been translated automatically.

Autosomal-recessive inherited metabolic disorder with increased iron absorption and consecutive hemosiderin deposition and tissue damage in various organs. The total iron content of the organism is increased from normally 3-5 g to 20-80 g.

Occurrence/Epidemiology
This section has been translated automatically.

Most common hereditary disease among members of the white race, prevalence (among Caucasians): 1/200-300 inhabitants.

Etiopathogenesis
This section has been translated automatically.

Classification of the different Hemochromatosis types:

  • Type 1 (classical hemochromatosis): Autosomal recessive mutations of the HFE 1 gene (Hereditary familial hemochromatosis gene 1; gene locus: 6p21.3). Prevalence of clinically manifest hemochromatosis in Europe 1:1,000; m:w=10:1 (cause: iron loss via menstruation).
  • Type 2 (juvenile haemochromatosis): rare, autosomal recessive mutations of the HFE 2 gene (hereditary familial haemochromatosis gene 2; gene locus: 1q21). Other forms of type 2 are caused by mutations of the hepcidin antimicrobial peptide gene (HAMP gene; gene locus: 19q13). Iron overload before the age of 30. Often heart failure and hypogonadism.
  • Type 3: Autosomal recessive mutations of the transferrin receptor-2 gene (TFR 2 gene; gene locus: 7q22).
  • Type 4: Autosomal-dominantly inherited mutations of the SLC11A3 gene (solute carrier family 11 A gene; gene locus: 2q32) with consecutive defect of ferroportin.

Manifestation
This section has been translated automatically.

This is particularly true for men at an older age (40-60 years). With the juvenile form (type 2) usually 10th-30th LJ.

Clinical features
This section has been translated automatically.

Iron overlay of <10g usually progresses clinically without tangible symptoms (latent stage). Higher tissue iron concentrations (>10g) initially lead to discrete changes and later to manifest hemosiderosis. Clinical manifestations of manifest hemochromatosis related to their percentage frequency:

  • liver cirrhosis (94%)
  • Skin lesions: (82%):
    • smoky-gray, blue-brown or bronze-like, patchy or extensive skin discolorations, especially pronounced on the face, armpits, genital region, also on the lower extremities (see Fig.) as well as on light-exposed areas and on scars
    • others: diffuse effluvium
  • hepatomegaly (76%)
  • weakness, fatigue (73%)
  • Potency- libido reduction (56%)
  • Diabetes mellitus (53%)
  • Upper abdominal pain (50%)
  • testicular atrophy (50%)
  • arthralgias (47%)
  • Cardiomyopathy (35%): There is an increasing deposition of iron in the sarcoplasm of the cardiac myocytes and consequent ventricular dysfunction. Dilatation of the ventricles with signs of heart failure is possible.

Histology
This section has been translated automatically.

Histology of the skin: Melanin proliferation in the basal stratum and haemosiderin deposits, especially in the deep corium.

Diagnosis
This section has been translated automatically.

History + Clinic; Laboratory: plasma ferritin ↑ (w=200ug/l; m=>300ug/l); transferrin saturation ↑ (w>45%; m>50%) - Remark: a normal trasferritin saturation largely excludes hemochromatosis. HFE genetic diagnosis (genetic findings can only be assessed in connection with clinical symptoms). Liver biopsy with iron detection (Berlin blue reaction)

Differential diagnosis
This section has been translated automatically.

Internist:

  • Iron overlays in hemolytic anemia, e.g. in myelodysplastic syndrome.
  • Alcoholic siderosis.
  • Siderosis in the context of chronic liver diseases

Dermatological (DD clinical macro aspect)

Therapy
This section has been translated automatically.

Internally: Low iron diet (avoid white beans, peas, lentils, leeks, soybeans, egg yolks, liver, heart, brewer's yeast).

Bloodletting 1 time per week (with 500 ml of blood an average of 250 mg iron is removed).

Iron chelators:

  • If necessary administration of deferoxamine (e.g. Desferal®), 100 mg deferoxamine binds 8 mg iron.
  • Alternative: Deferasirox

Progression/forecast
This section has been translated automatically.

If left untreated, the disease progresses progressively and leads to death within a few years.

Literature
This section has been translated automatically.

  1. Hanot VC, Chauffard AME (1882) Cirrhosis hypertrophique pigmentaire dans le diabète sucré. Rev Médecine (Paris) 2: 385-403
  2. Niederau C (2003) Hereditary hemochromatosis. Internist 44: 191-205
  3. Rihl M et al (2004) Arthropathy of hereditary hemochromatosis. Z Rheumatol 63: 22-29
  4. Troisier CE (1871) Diabète sucré.Bull Soc Anatomique (Paris) 16: 231
  5. From Recklinghausen FD (1889) About hemochromatosis. Berliner klin weekday 26: 92

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 13.10.2022